TickerFacts.

SpyGlass Pharma, Inc. (SGP): R&D Expense

Annual figures by period end, from SEC filings.

$29.18M
Year ended 2025-12-31
$35.28M
Trailing 12 months to 2026-06-30
2024-12-31: $19.98M2025-12-31: $29.18M$29.18M
2024-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$29.18M+46.0%2026-03-26, From 2025-01-01
2024-12-31$19.98Mn/a2026-03-26, From 2024-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
SpyGlass Pharma, Inc. (SGP)2025-12-31$29.18M+46.0%
Sight Sciences, Inc. (SGHT)2025-12-31$14.61M-18.8%
Orchestra BioMed Holdings, Inc. (OBIO)2025-12-31$58.19M+35.9%
Fractyl Health, Inc. (GUTS)2025-12-31$74.54M+5.8%
DarioHealth Corp. (DRIO)2025-12-31$13.79M-43.0%
Utah Medical Products Inc (UTMD)2025-12-31$668.0K-17.8%
Iradimed Corp (IRMD)2025-12-31$2.98M+5.0%
Delcath Systems, Inc. (DCTH)2025-12-31$29.25M+110.8%
Alpha Tau Medical Ltd. (DRTS)2025-12-31$32.06M+18.7%

Compare SGP, SGHT, OBIO, GUTS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗